MARKET

AFMD

AFMD

Affimed
NASDAQ
0.6850
-0.0150
-2.14%
After Hours: 0.6800 -0.005 -0.73% 19:57 05/09 EDT
OPEN
0.7000
PREV CLOSE
0.7000
HIGH
0.7200
LOW
0.6810
VOLUME
93.53K
TURNOVER
--
52 WEEK HIGH
8.95
52 WEEK LOW
0.5200
MARKET CAP
11.23M
P/E (TTM)
-0.1346
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AFMD last week (0428-0502)?
Weekly Report · 5d ago
Affimed Delays Filing of 2024 Yearly Report
TipRanks · 05/01 22:20
Weekly Report: what happened at AFMD last week (0421-0425)?
Weekly Report · 04/28 12:19
Affimed Says Abstract On Phase 2 LuminICE-203 Study Of ICE Acimtamig In Combination With AB-101 Accepted For Oral Presentation At ASCO 2025
Benzinga · 04/23 14:11
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
Barchart · 04/23 09:05
Affimed Faces Nasdaq Delisting Risk Due to Share Price
TipRanks · 04/21 12:57
Weekly Report: what happened at AFMD last week (0414-0418)?
Weekly Report · 04/21 12:18
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
NASDAQ · 04/21 10:41
More
About AFMD
More
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Recently
Symbol
Price
%Change
    SXI
  • 153.78
  • +0.40%

Webull offers Affimed NV stock information, including NASDAQ: AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.